FDA Approves Generic Lenacapavir, Bringing $40-a-Year HIV Prevention Shot Closer to 120 Low-Income Countries

The U.S. Food and Drug Administration has granted tentative approval to the first generic version of lenacapavir, the twice-yearly HIV prevention injection that has been hailed as a breakthrough in the fight against the epidemic. The decision, announced Monday, clears the way for the drug to be sold for approximately $40 per person per year in 120 low- and middle-income countries—a fraction of the $28,218 annual U.S. list price for Gilead Sciences' branded version, Yeztugo.

The generic is manufactured by India-based Dr. Reddy's Laboratories, which developed the product with financial, technical and regulatory support from Unitaid, the Clinton Health Access Initiative (CHAI) and the Wits Reproductive Health and HIV Institute (Wits RHI) . The approval came just 16 months after the FDA approved the originator product in June 2025—one of the fastest timelines for a major HIV innovation to date .

"This approval brings us a significant step closer to making this twice-yearly HIV prevention option available to people across low- and middle-income countries," said a Dr. Reddy's statement accompanying the announcement .

Why It Matters

Lenacapavir is a long-acting injectable HIV-1 capsid inhibitor administered every six months. In the pivotal PURPOSE 1 and PURPOSE 2 trials, it demonstrated near-complete protection against HIV acquisition: no infections among cisgender women in sub-Saharan Africa who received the injections in PURPOSE 1, and 97% efficacy among cisgender and transgender men who have sex with men in PURPOSE 2 . Resistance to the drug remained rare throughout the randomized blinded phases of both studies .

The convenience of a twice-yearly shot addresses a fundamental weakness of daily oral PrEP: adherence. "For someone at risk of HIV, taking a pill every day to prevent a disease they don't have is a hard thing to ask," said CHAI CEO Dr. Neil Buddy Shah. "Two injections a year, of a product that is almost 100% effective at preventing HIV, changes that entirely" .

According to the World Health Organization, 41 million people were living with HIV at the end of 2025, and 570,000 died from HIV-related causes that year . UNAIDS estimates that reaching 20 million people in highest need with prevention options—including men who have sex with men, sex workers, people who inject drugs, and young women and adolescent girls in sub-Saharan Africa—could dramatically reduce new infections and advance progress toward ending AIDS by 2030 .

The Pricing Architecture

The $40 annual price for the generic was secured through a landmark agreement announced in September 2025 between Unitaid, Wits RHI, CHAI and Dr. Reddy's, which combined an early pricing commitment with financial and technical support to accelerate development . Gilead Sciences separately signed royalty-free licensing agreements with six generic manufacturers, including Dr. Reddy's and Hetero Labs, covering 120 countries—primarily in sub-Saharan Africa, Asia and Latin America .

The branded version, Yeztugo, carries a U.S. list price of $28,218 per year before insurance, though Gilead officials say that is comparable to other forms of PrEP . The generic cannot be sold in the United States while Yeztugo remains under patent; the FDA's "tentative approval" designation is the standard regulatory pathway for generics during the originator's patent term, and is designed to ensure the quality of HIV-related drugs provided to other countries by the U.S. government .

Demand is already substantial. More than 125,000 people in 10 early-adopter African countries have started on Gilead's lenacapavir even before generic availability . First supplies of the generic are expected to reach countries before the end of 2026, with broader availability in 2027 .

Unfinished Business

Advocates welcomed the approval while noting significant gaps. The licensing agreements exclude upper-middle-income countries with substantial HIV burdens—including Brazil, Peru and Mexico, where the PURPOSE 2 trial was conducted—prompting ethicists to describe the exclusions as a "post-trial access failure" . Andrew Hill of the University of Liverpool noted that "30% of HIV transmission happens in countries excluded" from Gilead's licensing agreement .

Even at $40 per year, the price remains a barrier for some low-income health systems. Research suggests that at a volume of 2 million treatments annually, the generic could cost $35–46 per person per year, and with committed demand for 5–10 million people, the price could fall to $25 .

For Ghana and similar settings, translating clinical promise into public health impact will require more than an affordable product. A 2026 study of Ghanaian adults found that awareness and knowledge of lenacapavir remain low, though acceptability of long-acting injectable prevention is moderate. Perception was the strongest predictor of acceptability, and trust in health workers was a major facilitator. The authors concluded that "addressing informational gaps, affordability concerns, and perception-related barriers will be essential to translate Lenacapavir's clinical promise into a meaningful public health impact in Ghana" .

As Professor Saiqa Mullick of Wits RHI put it: "An affordable drug alone is not enough. Countries need health systems that are ready to deliver new prevention options, providers who are confident in offering them, and communities that are engaged as partners in their introduction and scale-up" .